January 2024

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Semin Arthritis Rheum 2024;65:152388 DOI: 10.1016/j.semarthrit.2024.152388 Epub ahead of print

Secukinumab efficacy regarding PROs and retention rate was comparable between axSpA and PsA patient groups when adjusted for confounders. Christiansen et al compared 6-, 12- and 24-month pain, fatigue, PGA, and HAQ PROs in axSpA and PsA patients treated with secukinumab, as well as 24-monthy retention rates in this real-world study.  

Keywords:

August 2023

乾癬性関節炎および体軸性脊椎関節炎治療に関するEULAR/ASAS-EULAR と欧州各国の治療推奨の類似点と相違点

Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706

Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.

Keywords:

October 2022

JAK阻害薬失敗後: 次のJAK阻害薬か変更か –それが問題だ JAK-pot collaboration レジストリ

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

July 2022

Secukinumab治療は TNF阻害薬よりも感染症リスクが高いか？北欧からの観察研究

Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac358

Glintborg B et al, highlight in their recent research from the Nordic countries, that there is a low frequency of hospitalised infections during treatment with secukinumab or TNFi in patients with SpA and PsA. In clinical practice, secukinumab was found to double absolute risk of 1st year hospitalised infection compared with adalimumab, with the other TNFi treatments falling in between.

Keywords:

June 2022

JAK-pot collaborationにおける19レジストりを基にした 31846名の関節リウマチ患者におけるTNF阻害薬, アバ タセプト, IL-6阻害薬, JAK阻害薬の有効性

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

Keywords: